Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
出版年份 2022 全文链接
标题
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
作者
关键词
-
出版物
Cardiovascular Diabetology
Volume 21, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-09-02
DOI
10.1186/s12933-022-01604-7
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
- (2022) Dominik Dahl et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- 720-P: Change in Body Weight from Baseline with Tirzepatide: Sex Subgroup Analysis of the SURPASS Studies
- (2022) ARIAN W. PLAT et al. DIABETES
- 743-P: Effect of Once-Weekly TZP on Glycemic Control by Baseline Age in Patient Subpopulations from the SURPASS Trials
- (2022) CAROL H. WYSHAM et al. DIABETES
- 717-P: Glycemic Control with Tirzepatide in People with Type 2 Diabetes by Baseline HbA1c =8.5% or >8.5%
- (2022) GRAZIA ALEPPO et al. DIABETES
- 90-LB: Characterization of Tirzepatide-Treated patients achieving HbA1c <5.7% in the SURPASS 1-4 Trials
- (2022) JULIO ROSENSTOCK et al. DIABETES
- 719-P: Tirzepatide Induces Weight Loss in Patients with Type 2 Diabetes Regardless of Baseline BMI: A Post Hoc Analysis of SURPASS-1 through -5 Studies
- (2022) ANITA KWAN et al. DIABETES
- 727-P: Glycemic Effect of Tirzepatide by Duration of Diabetes
- (2022) CHRISTOPHE DE BLOCK et al. DIABETES
- 338-OR: Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People with T2D
- (2022) TIM HEISE et al. DIABETES
- 729-P: Relationship between Body Weight Change and Glycemic Control with Tirzepatide Treatment in People with Type 2 Diabetes
- (2022) SUE PEDERSEN et al. DIABETES
- Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
- (2022) Naveed Sattar et al. NATURE MEDICINE
- Structural determinants of dual incretin receptor agonism by tirzepatide
- (2022) Bingfa Sun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease
- (2022) Jun Sung Moon et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
- (2022) Tim Heise et al. Lancet Diabetes & Endocrinology
- Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
- (2022) Amalia Gastaldelli et al. Lancet Diabetes & Endocrinology
- Tirzepatide Once Weekly for the Treatment of Obesity
- (2022) Ania M. Jastreboff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
- (2021) Shweta Urva et al. CLINICAL PHARMACOKINETICS
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
- (2021) Lone B Enebo et al. LANCET
- Genetically Predicted Glucose-Dependent Insulinotropic Polypeptide (Gip) Levels and Cardiovascular Disease Risk are Driven by Distinct Causal Variants in the Gipr Region
- (2021) Nicholas Bowker et al. DIABETES
- GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist Induced Nausea and Emesis in Preclinical Models
- (2021) Tito Borner et al. DIABETES
- Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
- (2021) Rajaa Nahra et al. DIABETES CARE
- The evolving story of incretins ( GIP and GLP ‐1) in metabolic and cardiovascular disease: A pathophysiological update
- (2021) Michael A. Nauck et al. DIABETES OBESITY & METABOLISM
- The Dual GIP and GLP ‐1 Receptor Agonist Tirzepatide Improves Cardiovascular Risk Biomarkers in Patients with Type 2 Diabetes: a Post‐Hoc Analysis
- (2021) Jonathan M Wilson et al. DIABETES OBESITY & METABOLISM
- Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling
- (2021) Ville Karhunen et al. DIABETOLOGIA
- Consensus report: definition and interpretation of remission in type 2 diabetes
- (2021) Matthew C. Riddle et al. DIABETOLOGIA
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
- (2021) Julio Rosenstock et al. LANCET
- Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
- (2021) Bernhard Ludvik et al. LANCET
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
- (2021) Michael A Nauck et al. Lancet Diabetes & Endocrinology
- A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes
- (2021) Kenichi Furihata et al. DIABETES OBESITY & METABOLISM
- Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes
- (2021) Valentina Pirro et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
- (2021) Stefano Del Prato et al. LANCET
- Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
- (2021) Ildiko Lingvay et al. LANCET
- Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation
- (2021) Alessia Costa et al. Molecular Metabolism
- Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens
- (2020) Juan Pablo Frias et al. DIABETES OBESITY & METABOLISM
- Glucose-dependent insulinotropic peptide and risk of cardiovascular events and mortality: a prospective study
- (2020) Amra Jujić et al. DIABETOLOGIA
- GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals
- (2020) Lærke S Gasbjerg et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- How May GIP Enhance the Therapeutic Efficacy of GLP-1?
- (2020) Ricardo J. Samms et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes
- (2020) Jonathan M. Wilson et al. DIABETES OBESITY & METABOLISM
- Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism
- (2020) Elizabeth A. Killion et al. Nature Communications
- GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
- (2020) Michael A. Nauck et al. Molecular Metabolism
- Glucose-Dependent Insulinotropic Peptide in the High-Normal Range Is Associated With Increased Carotid Intima-Media Thickness
- (2020) Amra Jujić et al. DIABETES CARE
- The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
- (2020) Thinzar Min et al. Diabetes Therapy
- Separate and Combined Gluco-Metabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 in Healthy Individuals
- (2019) Lærke S. Gasbjerg et al. DIABETES
- Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial
- (2019) Michael E J Lean et al. Lancet Diabetes & Endocrinology
- Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study
- (2019) Natasha C. Bergmann et al. DIABETOLOGIA
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies For The Treatment Of Obesity, Do Agonists = Antagonists?
- (2019) Elizabeth A Killion et al. ENDOCRINE REVIEWS
- Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists
- (2019) Lærke S. Gasbjerg et al. PEPTIDES
- Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease
- (2019) Sebastian M. Heimbürger et al. PEPTIDES
- The glucose-dependent insulinotropic polypeptide signaling axis in the central nervous system
- (2019) A.E. Adriaenssens et al. PEPTIDES
- MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
- (2019) Michael A Nauck et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme
- (2018) J. Hans DeVries et al. DIABETES OBESITY & METABOLISM
- Incretin hormones: Their role in health and disease
- (2018) Michael A. Nauck et al. DIABETES OBESITY & METABOLISM
- Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial
- (2018) Michael EJ Lean et al. LANCET
- Peptide-based multi-agonists: a new paradigm in metabolic pharmacology
- (2018) Sara J. Brandt et al. JOURNAL OF INTERNAL MEDICINE
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
- (2018) Tamer Coskun et al. Molecular Metabolism
- Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
- (2017) Vanita R Aroda et al. Lancet Diabetes & Endocrinology
- Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists
- (2015) Brian Finan et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Glucose-dependent Insulinotropic Polypeptide: Blood Glucose Stabilizing Effects in Patients With Type 2 Diabetes
- (2013) Mikkel B. Christensen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
- (2013) B. Finan et al. Science Translational Medicine
- Regulation of Food Intake, Energy Balance, and Body Fat Mass: Implications for the Pathogenesis and Treatment of Obesity
- (2012) Stephan J. Guyenet et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Glucose-Dependent Insulinotropic Polypeptide: A Bifunctional Glucose-Dependent Regulator of Glucagon and Insulin Secretion in Humans
- (2011) M. Christensen et al. DIABETES
- GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes
- (2011) N. Mentis et al. DIABETES
- Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired -Cell Function?
- (2010) J. J. Meier et al. DIABETES
- Exogenous Glucose-Dependent Insulinotropic Polypeptide Worsens Post prandial Hyperglycemia in T ype 2 Diabetes
- (2009) C. W. Chia et al. DIABETES
- A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
- (2009) Jonathan W Day et al. Nature Chemical Biology
- Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes
- (2008) P. V. Højberg et al. DIABETOLOGIA
- Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies
- (2008) J. D. Roth et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started